替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移瘤的效果观察被引量：5

下载PDF

导出

摘要目的:观察替莫唑胺联合全脑放疗治疗非小细胞肺癌(NSCLC)脑转移瘤的效果。方法:选择2014年1月至2015年12月四川省自贡市第四人民医院收治的124例NSCLC脑转移瘤患者为研究对象,按随机数字表法分为观察组和对照组,每组62例。对照组给予全脑放疗治疗,观察组给予替莫唑胺联合全脑放疗治疗,比较两组近期疗效、血清肿瘤标志物、免疫功能和不良反应等情况。结果:观察组缓解率和疾病控制率明显高于对照组(P<0.05),观察组血清癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)含量明显低于对照组(P<0.01);T淋巴细胞亚群CD3+、CD4+、CD4+/CD5+明显高于对照组,CD8+明显低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:替莫唑胺联合全脑放疗可提高NSCLC脑转移瘤患者的临床疗效,降低患者肿瘤标志物含量,减轻免疫功能损伤。

作者李家伟肖雯艳

机构地区四川省自贡市第四人民医院肿瘤科四川省自贡市第四人民医院门诊办公室

出处《广西医科大学学报》 CAS 2018年第7期980-983,共4页 Journal of Guangxi Medical University

关键词非小细胞肺癌脑转移瘤替莫唑胺肿瘤标志物免疫功能

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1苏雷,胡玲,崔桂敏,霍燃,张建军,李小芳,徐妍.MGMT及IDH1表达与替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移疗效的关系[J].重庆医学,2017,46(21):2976-2979. 被引量：23
2韦燕,赵善琳,黄店.肿瘤的中医病机和治疗原则及替莫唑胺联合放疗治疗肺癌脑转移疗效分析[J].环球中医药,2014,7(S1):82-83. 被引量：6
3杨永辉,李欣欣,杨璟.脑转移瘤再次放疗联合替莫唑胺治疗与单纯再次放疗的疗效比较[J].中国老年学杂志,2014,34(3):631-633. 被引量：7
4李子煌,李先明,杨东,周亚燕,徐钢,李壮玲,龚龙.替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移瘤的疗效观察[J].广东医学,2017,38(10):1593-1597. 被引量：35
5张朝巍.牛蒡子苷元对大鼠脑胶质瘤细胞增殖及其瘤体生长的抑制作用[J].山东医药,2017,57(21):41-43. 被引量：3
6滕菲,崔桂敏,史鸿云,刘妙玲,李延红.放疗联合替莫唑胺治疗非小细胞肺癌脑转移瘤的临床观察[J].国际肿瘤学杂志,2017,44(4):271-273. 被引量：11
7李鹤飞,丁亚楠,石林,单小松,梁朝辉,向莎莎.非小细胞肺癌脑转移患者手术治疗医院感染相关因素分析[J].中华医院感染学杂志,2015,25(13):3034-3036. 被引量：5
8刘艳萍,曾爱屏,宋向群,周韶璋,于起涛.肿瘤标志物与非小细胞肺癌脑转移的相关性[J].现代肿瘤医学,2015,23(19):2777-2781. 被引量：12
9赵文华,刘艳萍,于起涛,周韶璋,宋向群.血清CEA水平与晚期非小细胞肺癌患者脑转移的相关因素分析[J].广西医科大学学报,2015,32(3):401-404. 被引量：5
10姜永红,朱盼盼,穆少锋,李少欣.肺癌手术患者抑郁状态对免疫代谢的影响[J].国际精神病学杂志,2017,44(1):109-111. 被引量：5

二级参考文献78

1Gang Li,Yong-sheng Hu,Xin-gang Li,Qing-lin Zhang,Dong-hai Wang,Song-feng Gong.EXPRESSION AND SWITCHING OF TH1/TH2 TYPE CYTOKINESGENE IN HUMAN GLIOMAS[J].Chinese Medical Sciences Journal,2005,20(4):268-272. 被引量：5
2石安辉,朱广迎,余荣,马惠民,刘长青,苏星,孙艳,蔡勇,徐晓娜,张珊文,徐博.非小细胞肺癌伴脑转移放疗疗效分析[J].中华肿瘤杂志,2007,29(7):545-548. 被引量：15
3Paul W. Sperduto,Norbert Kased,David Roberge,Zhiyuan Xu,Ryan Shanley,Xianghua Luo,Penny K. Sneed,Samuel T. Chao,Robert J. Weil,John Suh,Amit Bhatt,Ashley W. Jensen,Paul D. Brown,Helen A. Shih,John Kirkpatrick,Laurie E. Gaspar,John B. Fiveash,Veronica Chiang,Jonathan P.S. Knisely,Christina Maria Sperduto,Nancy Lin,Minesh Mehta.Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases[J].International Journal of Radiation Oncology Biology Physics.2012(5)
4Masaaki Yamamoto,Yasunori Sato,Toru Serizawa,Takuya Kawabe,Yoshinori Higuchi,Osamu Nagano,Bierta E. Barfod,Junichi Ono,Hidetoshi Kasuya,Yoichi Urakawa.Subclassification of Recursive Partitioning Analysis Class II Patients With Brain Metastases Treated Radiosurgically[J].International Journal of Radiation Oncology Biology Physics.2012(5)
5Amanda Caissie,Janet Nguyen,Emily Chen,Liying Zhang,Arjun Sahgal,Mark Clemons,Marc Kerba,Palmira Foro Arnalot,Cyril Danjoux,May Tsao,Elizabeth Barnes,Lori Holden,Brita Danielson,Edward Chow.Quality of Life in Patients With Brain Metastases Using the EORTC QLQ-BN20+2 and QLQ-C15-PAL[J].International Journal of Radiation Oncology Biology Physics.2012(4)
6James J. Vredenburgh,Annick Desjardins,John P. Kirkpatrick,David A. Reardon,Katherine B. Peters,James E. Herndon,Jennifer Marcello,Leighann Bailey,Stevie Threatt,John Sampson,Allan Friedman,Henry S. Friedman.Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme[J].International Journal of Radiation Oncology Biology Physics.2012(1)
7Petrovic M,nic N, Loncarevic O,et al. Risk factors for brain metastases in surgically staged IIIA non-small cell lung cancer patients treated with surgery, radiotherapy and chemotherapy [J]. Vojnosanit Pregl,2011,68(8) :643-649.
8Cohen-Inbar O, Sheehan JP. Perspective-Fighting cancer on all fronts~ stereotaetic radiosurgery and the role for aggres- sive primary treatment in non-small cell lung cancer patients with one brain metastasis[J]. World Neurosurg,2015,3(5) : S1878-8750.
9Leblebicioglu H, Erben N, Rosenthal VD, et al. Surgical site infection rates in 16 cities in Turkey: findings of the interna- tional nosocomial infection control consortium (IN1CC)~J]. Am J Infect Control,2015,43(1) :48-52.
10Kimmell KT, Jahromi BS. Clinical factors associated with ve- nous thromboembolism risk in patients undergoing cranioto- my[J]. J Neurosurg,2014,12(12) :1-8.